Simcere Pharmaceutical Group Limited clinical trials

The registry lists 80 studies whose lead sponsor is Simcere Pharmaceutical Group Limited or one of 3 companies grouped under it. 14 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 22, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 80. Browse all 80 →

• Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple MyelomaRecruitingNCT06375044Phase 1

  Sponsor listed in the registry: Jiangsu Simcere Pharmaceutical Co., Ltd.

• A Study of SIM0689 in Adult Participants With Locally Advanced or Metastatic Solid TumorsRecruitingNCT07660432Phase 1

  Sponsor listed in the registry: Jiangsu Simcere Pharmaceutical Co., Ltd.

• SIM0613 in Participants With Advanced Solid TumorsRecruitingNCT07618260Phase 1

  Sponsor listed in the registry: Jiangsu Simcere Pharmaceutical Co., Ltd.

• First in Human Study of SIM0610 in Solid TumorsRecruitingNCT07348211Phase 1

  Sponsor listed in the registry: Jiangsu Simcere Pharmaceutical Co., Ltd.

• An Open-Label Drug Interaction Clinical Study to Evaluate Itraconazole, Rifampin, Midazolam and SIM0270 in Chinese Healthy Adult ParticipantsRecruitingNCT07357610Phase 1

  Sponsor listed in the registry: Jiangsu Simcere Pharmaceutical Co., Ltd.

• A Phase Ib/III Study of Suvemcitug Plus FTD/TPI in Participants With Refractory Metastatic Colorectal CancerRecruitingNCT07361003Phase 3

  Sponsor listed in the registry: Jiangsu Simcere Pharmaceutical Co., Ltd.

• A Phase I Study of SIM0609 in Adult Participants With Locally Advanced/Metastatic Solid TumorsRecruitingNCT07265921Phase 1

  Sponsor listed in the registry: Jiangsu Simcere Pharmaceutical Co., Ltd.

• A Phase 2 Study to Evaluate the Efficacy, Safety of SIM0278 in Subjects With Moderate to Severe Atopic DermatitisNot yet recruitingNCT07175233Phase 2

  Sponsor listed in the registry: Jiangsu Simcere Pharmaceutical Co., Ltd.

• A Phase I Study of SIM0686 in Participants With Locally Advanced/Metastatic Solid TumorsRecruitingNCT07050459Phase 1

  Sponsor listed in the registry: Jiangsu Simcere Pharmaceutical Co., Ltd.

• A Phase I Study of SIM0388 in Participants With Malignant Ascites.RecruitingNCT07007988Phase 1

  Sponsor listed in the registry: Jiangsu Simcere Pharmaceutical Co., Ltd.

• A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SIM0237 Alone or in Combination with BCG in NMIBCRecruitingNCT06186414Phase 1

  Sponsor listed in the registry: Jiangsu Simcere Pharmaceutical Co., Ltd.

• Study of SIM0508 Alone and in Combination in Patients With Advanced Solid TumorsRecruitingNCT06686745Phase 1

  Sponsor listed in the registry: Jiangsu Simcere Pharmaceutical Co., Ltd.

• A Phase I Trial of SIM1811-03 in Subjects With Advanced TumorsRecruitingNCT05781386Phase 1

  Sponsor listed in the registry: Jiangsu Simcere Biologics Co., Ltd

• A Study to Investigate the Safety and Tolerability of SCR-6920 Capsule in Patients With Advanced Malignant TumorsRecruitingNCT05528055Phase 1

  Sponsor listed in the registry: Jiangsu Simcere Pharmaceutical Co., Ltd.

• A Phase I, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of SIM0811 Injection in Healthy Chinese Adult ParticipantsCompletedNCT07345364Phase 1

  Sponsor listed in the registry: Jiangsu Simcere Pharmaceutical Co., Ltd.

• A Phase III, Randomized, Double-blind, Multi-center Trial Comparing Efficacy and Safety of Trilaciclib Versus Placebo in Participants With Limited-stage Small Cell Lung CancerActive, not recruitingNCT07881705Phase 3

  Sponsor listed in the registry: Jiangsu Simcere Pharmaceutical Co., Ltd.

• An Open Label, Multi-center, Phase I Clinical Study to Evaluate the Safety, Effectiveness and Pharmacokinetic Characteristics of SIM1803-1A in Patients With Locally Advanced/Metastatic Solid Tumors With NTRK, ROS1 or ALK Gene Fusion Mutations.TerminatedNCT04671849Phase 1

  Sponsor listed in the registry: Jiangsu Simcere Pharmaceutical Co., Ltd.

• Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0348 in Advanced Solid TumorsTerminatedNCT05718219Phase 1

  Sponsor listed in the registry: Jiangsu Simcere Pharmaceutical Co., Ltd.

• A Study of SIM0270 Combined With Everolimus vs. Treatment of Physician's Choice in Patients With ER+/HER2- Advanced Breast Cancer (SIMRISE)Active, not recruitingNCT06680921Phase 3

  Sponsor listed in the registry: Jiangsu Simcere Pharmaceutical Co., Ltd.

• A Phase I Study of SIM0532 in Adult Participants With Advanced Solid TumorsActive, not recruitingNCT07749703Phase 1

  Sponsor listed in the registry: Jiangsu Simcere Pharmaceutical Co., Ltd.

• Study of SIM0501 Alone and in Combination in Patients With Advanced Solid TumorsTerminatedNCT06331559Phase 1

  Sponsor listed in the registry: Jiangsu Simcere Pharmaceutical Co., Ltd.

• A Phase Ⅲ Clinical Study of Combined Cisplatin Versus Placebo Combined With Intracavitary Cisplatin Injection in the Treatment of Malignant Pleural EffusionsActive, not recruitingNCT04914598Phase 3

  Sponsor listed in the registry: Jiangsu Simcere Pharmaceutical Co., Ltd.

• A Phase III Study of BD0801 Combined With Chemotherapy in Recurrent, Platinum-resistant Epithelial Ovarian CancerCompletedNCT04908787Phase 3

  Sponsor listed in the registry: Jiangsu Simcere Pharmaceutical Co., Ltd.

• To Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SIM0278 in Chinese Healthy SubjectsCompletedNCT06022354Phase 1

  Sponsor listed in the registry: Jiangsu Simcere Pharmaceutical Co., Ltd.

• A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0237 in Adult Participants with Advanced Solid TumorsTerminatedNCT05781360Phase 1

  Sponsor listed in the registry: Jiangsu Simcere Pharmaceutical Co., Ltd.

• Evaluate the Effects of Food on the Pharmacokinetics of SIM0270CompletedNCT06536036Phase 1

  Sponsor listed in the registry: Jiangsu Simcere Pharmaceutical Co., Ltd.

• Phase I Study to Evaluate SIM0270 Alone or in Combination in ER+, HER2- Locally Advanced or Metastatic Breast CancerActive, not recruitingNCT05293964Phase 1

  Sponsor listed in the registry: Jiangsu Simcere Pharmaceutical Co., Ltd.

• Mass Balance Clinical Trial of SIM0270Active, not recruitingNCT06654791Phase 1

  Sponsor listed in the registry: Jiangsu Simcere Pharmaceutical Co., Ltd.

• A Study of Daridorexant in Chinese Patients With Insomnia DisorderCompletedNCT06010693Phase 3

  Sponsor listed in the registry: Jiangsu Simcere Pharmaceutical Co., Ltd.

• Phase 3 Study Evaluating Efficacy, Safety and Pharmacokinetics of Trilaciclib In Small Cell Lung Cancer PatientsCompletedNCT04902885Phase 3

  Sponsor listed in the registry: Jiangsu Simcere Pharmaceutical Co., Ltd.

• Investigate the PK, Safety, and Tolerability After Single and Multiple Dose Daridorexant in Chinese Healthy SubjectsCompletedNCT06326723Phase 1

  Sponsor listed in the registry: Jiangsu Simcere Pharmaceutical Co., Ltd.

• A Phase II Study of Envofolimab and BD0801 With/Without Chemotherapy in Patients With Advanced Solid TumorsTerminatedNCT05148195Phase 2

  Sponsor listed in the registry: Jiangsu Simcere Pharmaceutical Co., Ltd.

• The Tolerability, Safety, and PK Characteristics of SIM1910-09 in Healthy Chinese VolunteersCompletedNCT05200728Phase 1

  Sponsor listed in the registry: Jiangsu Simcere Pharmaceutical Co., Ltd.

• Evaluation of TRILACICLIB in Chinese Patients With Extensive-stage Small Cell Lung Cancer (ES-SCLC) for Chemotherapy-induced Myelosuppression, Antitumor Effects of Combination Regimens, and Safety in a Real-world StudyCompletedNCT05071703Phase 4

  Sponsor listed in the registry: Jiangsu Simcere Pharmaceutical Co., Ltd.

• To Evaluate SSD8432/ Ritonavir in Adults With COVID-19CompletedNCT05369676Phase 1/2

  Sponsor listed in the registry: Jiangsu Simcere Pharmaceutical Co., Ltd.

• A Clinical Study to Evaluate the Efficacy and Safety of SIM0417 Orally Co-Administered With Ritonavir in Symptomatic Adult Participants With Mild to Moderate COVID-19CompletedNCT05506176Phase 2/3

  Sponsor listed in the registry: Jiangsu Simcere Pharmaceutical Co., Ltd.

• Safety and Pharmacokinetics of SIM0417 Combined With Ritonavir in Healthy Elderly SubjectsStatus unknownNCT05826249Phase 1

  Sponsor listed in the registry: Jiangsu Simcere Pharmaceutical Co., Ltd.

• Hepatic Impairment and Renal Impairment Study of SIM0417 Combined With RitonavirStatus unknownNCT05731804Phase 1

  Sponsor listed in the registry: Jiangsu Simcere Pharmaceutical Co., Ltd.

• Drug-Drug Interaction Study of Itraconazole, Rifampicin and Midazolam With SIM0417/Ritonavir in Healthy ParticipantsCompletedNCT05665647Phase 1

  Sponsor listed in the registry: Jiangsu Simcere Pharmaceutical Co., Ltd.

• A Phase I Trial of SIM1811-03 in Subjects With Advanced Solid Tumors and Cutaneous T-cell LymphomaStatus unknownNCT05569057Phase 1

  Sponsor listed in the registry: Jiangsu Simcere Pharmaceutical Co., Ltd.

• Study to Investigate the Mass Balance and Biotransformation of SIM0417 in Healthy Adult Chinese Male ParticipantsCompletedNCT05475834Phase 1

  Sponsor listed in the registry: Jiangsu Simcere Pharmaceutical Co., Ltd.

• Evaluation of SSD8432 and Ritonavir in Adult Subjects With COVID-19 Clinical StudyStatus unknownNCT05373446Phase 2

  Sponsor listed in the registry: Jiangsu Simcere Pharmaceutical Co., Ltd.

• To Evaluate SSD8432/Ritonavir in Adults With COVID-19Status unknownNCT05373433Phase 2/3

  Sponsor listed in the registry: Jiangsu Simcere Pharmaceutical Co., Ltd.

• A Phase I Clinical Study of SSD8432 in Healthy Adult SubjectsStatus unknownNCT05339646Phase 1

  Sponsor listed in the registry: Jiangsu Simcere Pharmaceutical Co., Ltd.

• A Study of Docetaxel Polymeric Micelles for Injection in Patients With Advanced Solid TumorsStatus unknownNCT05254665Phase 2

  Sponsor listed in the registry: Jiangsu Simcere Pharmaceutical Co., Ltd.

• A Study to Evaluate the Efficacy and Safety of Iguratimod Compared to Placebo in Patients With Active Primary Sjogren's Syndrome.Status unknownNCT04830644Phase 2

  Sponsor listed in the registry: Jiangsu Simcere Pharmaceutical Co., Ltd.

• PK Study for Endostar Continuous Intravenous Infusion in NSCLC Patients With 1st-line Platinum Based ChemotherapyStatus unknownNCT04942301Phase 1

  Sponsor listed in the registry: Jiangsu Simcere Pharmaceutical Co., Ltd.

• A Study of Iguratimod in Patients With Active Rheumatoid ArthritisCompletedNCT01554917Phase 4

  Sponsor listed in the registry: Jiangsu Simcere Pharmaceutical Co., Ltd.

• A Phase Ib Study With Pegylated Recombinant Human Endostatin in Advanced / Metastatic NSCLC or Other Solid TumorsStatus unknownNCT04413227Phase 1

  Sponsor listed in the registry: Jiangsu Simcere Pharmaceutical Co., Ltd.

• A Phase 1b Study of Sevacizumab in Combination With Chemotherapy in Chinese Patients With Platinum-Resistant Recurrent Ovarian Cancer.Status unknownNCT03763123Phase 1

  Sponsor listed in the registry: Jiangsu Simcere Pharmaceutical Co., Ltd.